Get started
Emergent BioSolutions Inc.Emergent BioSolutions Inc.Emergent BioSolutions Inc.

Emergent BioSolutions Inc.

No trades
See on Supercharts
Overview Financials News
Ideas
Discussions Technicals Forecast Seasonals Bonds

EBS trade ideas

EMERGENT BIOSOLUTIONS Plan DailyHello traders, EMERGENT BIOSOLUTIONS is in a fake bearish push with a return of executed buy volume and a large hammer candle. Looking at the TIMEFRAME M1 we see a dash with a negotiated buy volume return, she came to the base of the bollinger to test it. And move up to the comfort zone to check it again. There is a great chance of breaking the price, with the momentum in the same moment the zone to slip on the next one and go on the high which follows. With three resistances to yield before a breakout of a comfort eon three on the TIMEFRAME H1 + filling a bearish breakout gap and six on the TIMEFRAME H1. Not enough force to test half of the intermediate median of ANDREWS PITCHFORK. Please LIKE & FOLLOW, thank you!
NYSE:EBSShort
by stephanelibatd
4
ABC BullishBollinger bands are tight so it looks like this will break one way or the other in the near future. A clear uptrend must be in place and the trendline BC must be broken. BC leg has been broken but not quite a clear uptrend in place yet. Entry can be where you feel comfortable as there is a lot of R overhead. This one has a history of gapping down so be safe. I see R at 107.4 but there is support close by right now The 50, 100 and 200 moving averages are all where they are supposed to be and tilting slightly up The 20 which is the BBand MA is flat NV is high Not a recommendation
NYSE:EBSLong
by lauralea
2
EBS: Operation Warp Speed TimelineEmergent BioSolutions is well known for owning the rights to the pioneering technology behind the Narcan nasal spray. Naloxone has been around for years as an injectable for opioid overdoses which required expertise to administer. Narcan spray eliminated the expertise requirement. Recently, EBS entered into several large contracts with giant pharma and will serve as manufacturers of leading COVID-19 vaccine candidates. They are working with Department of Defense; Department of Health and Human Services; Johnson & Johnson; and AstraZeneca. The deal with JNJ starts in 2021 and lasts 5 years. As more and more vaccines pass trials and get approved, biotech companies will need a manufacturer to sign with and I believe that EBS will be the go-to because of their size and ability to scale. Currently waiting for a buy signal.
NYSE:EBSLong
by ZombieStar
6
Gap is my Middle nameThis stock goes up, then gaps down, goes up, gaps down. Would not be fun to own a whole lot of it! Is a virus stock so I am sure gaps are probably based on news No pattern in particular..just a gap stock/volatile as a vocano.. providing support and resistance Earnings 7-30 amc and they do miss at times/short is not as high right now as I would think/perhaps it will rise with the stock cos chances are..it will gap down again! Emergent BioSolutions Inc., a life sciences company, focuses on the provision of specialty products for civilian and military populations that address accidental, deliberate, and naturally occurring public health threats (PHTs). The company's products address PHTs, which include chemical, biological, radiological, nuclear, and explosives; emerging infectious diseases; travel health; and emerging health crises and acute/emergency care. It offers BioThrax, an anthrax vaccine; ACAM2000, a smallpox vaccine; Vaxchora, a cholera vaccine; and Vivotif, a typhoid vaccine. The company also provides NARCAN for the emergency treatment of known or suspected opioid overdose; Reactive Skin Decontamination Lotion Kit, a medical device to remove or neutralize chemical warfare agents from the skin; and Trobigard a combination drug-device auto injector product candidate. In addition, it offers raxibacumab for the treatment and prophylaxis of inhalational anthrax; Anthrasil to treat inhalational anthrax; Botulism Antitoxin Heptavalent for treating botulinum disease; vaccinia immune globulin intravenous that addresses complications from smallpox vaccination; CHIKUNGUNYA, a chikungunya virus-like particle vaccine; and ADENOVIRUS 4/7. Further, the company offers other discovery and preclinical product candidates addressing PHTs, including viral hemorrhagic fevers caused by Ebola, Marburg, Sudan, and Lassa viruses; diarrheal disease caused by Shigella; and heat-labile toxin producing enterotoxigenic Escherichia coli, etc. Additionally, it offers FLU-IGIV to treat Influenza A infection; and ZIKV-IG, a prophylaxis for Zika infections, as well as contract development and manufacturing services to pharma and biotech industries, and government agencies/non-governmental organizations. The company has collaboration agreements with Novavax Inc.; and Johnson & Johnson. Emergent BioSolutions Inc. was founded in 1998 and is headquartered in Gaithersburg, Maryland.
NYSE:EBS
by lauralea
8
GOOD OPPORTUNITY-LONG COVERS-STRONG LEVELWonderful classic setup- hyper growth facing a strong level! I do not care about the fundamentals. I just know, that facing a good level is a great opportunity for people to cover their longs and take profit. So, unless we see an instant breakout, and the price stops at the level, people will start covering parts of their positions, and the big buyer will stop being so aggressive, hoping to get more volume at this level! Basic Technicals! All you need is a chart! probability of the trade is about 50%, with the risk reward being over 1:3 GOOD OPPORTUNITY!
NYSE:EBSShort
by StocksAndOptons
1